Jameson Tl Berry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jameson Tl Berry has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bernardo Alfredo Mainou
Division of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publication - Johnasha D. Stuart
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
1 shared publication - Karl William Boehme
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences
1 shared publication - Matthew B Phillips
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Atlanta, GA, USA
1 shared publication - Roxana M Rodríguez Stewart
Department of Pediatrics, Emory University, Atlanta, GA, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2018
- Published by Taylor & Francis in Oncolytic Virotherapy
- Vol. ume 7, 53-63
Current understanding of reovirus oncolysis mechanisms
Mammalian orthoreovirus (reovirus) is under development as a cancer virotherapy. Clinical trials demonstrate that reovirus-based therapies are safe and tolerated in patients with a wide variety of cancers. Although reovirus monotherapy has proven largely ineffective, reovirus sensitizes cancer cells to existing chemotherapeutic agents and radiation. Clinical trials are underway to test the efficacy of reovirus in combination with chemotherapeutic and radiation regimens and to evaluate the effectiveness of reovirus in conjunction with immunotherapies. Central to the use of reovirus to treat cancer is its capacity to directly kill cancer cells and alter the cellular environment to augment other therapies. Apoptotic cell death is a prominent mechanism of reovirus cancer cell killing. However, reoviruses can also kill cancer cells through nonapoptotic mechanisms. Here, we describe mechanisms of reovirus cancer cell killing, highlight how reovirus is used in combination with existing cancer treatments, and discuss what is known as to how reovirus modulates cancer immunotherapy.
- 1 June 2018
- Published by Taylor & Francis in Oncolytic Virotherapy
- Vol. ume 7, 53-63
Open AccessCurrent understanding of reovirus oncolysis mechanisms
Mammalian orthoreovirus (reovirus) is under development as a cancer virotherapy. Clinical trials demonstrate that reovirus-based therapies are safe and tolerated in patients with a wide variety of cancers. Although reovirus monotherapy has proven largely ineffective, reovirus sensitizes cancer cells to existing chemotherapeutic agents and radiation. Clinical trials are underway to test the efficacy of reovirus in combination with chemotherapeutic and radiation regimens and to evaluate the effectiveness of reovirus in conjunction with immunotherapies. Central to the use of reovirus to treat cancer is its capacity to directly kill cancer cells and alter the cellular environment to augment other therapies. Apoptotic cell death is a prominent mechanism of reovirus cancer cell killing. However, reoviruses can also kill cancer cells through nonapoptotic mechanisms. Here, we describe mechanisms of reovirus cancer cell killing, highlight how reovirus is used in combination with existing cancer treatments, and discuss what is known as to how reovirus modulates cancer immunotherapy.